These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 14073014)

  • 1. DISCUSSION ON EXPERIMENTAL TUMORS; THE IMMUNE STATE INVOLVED IN SUBCUTANEOUS IMPLANTS OF PROSTATIC TISSUE.
    BISHOP DW
    Natl Cancer Inst Monogr; 1963 Oct; 12():409-11. PubMed ID: 14073014
    [No Abstract]   [Full Text] [Related]  

  • 2. DISCUSSION ON EXPERIMENTAL TUMORS; CRITERIA FOR DESIRABLE TUMOR SYSTEMS.
    SCHIRMER H
    Natl Cancer Inst Monogr; 1963 Oct; 12():405-6. PubMed ID: 14073012
    [No Abstract]   [Full Text] [Related]  

  • 3. A TRANSPLANTABLE, SPONTANEOUS ADENOCARCINOMA OF THE PROSTATE IN THE SYRIAN (GOLDEN) HAMSTER.
    FORTNER JG; FUNKHAUSER JW; CULLEN MR
    Natl Cancer Inst Monogr; 1963 Oct; 12():371-9. PubMed ID: 14073010
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
    Sheridan T; Herawi M; Epstein JI; Illei PB
    Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.
    Snoek R; Cheng H; Margiotti K; Wafa LA; Wong CA; Wong EC; Fazli L; Nelson CC; Gleave ME; Rennie PS
    Clin Cancer Res; 2009 Jan; 15(1):39-47. PubMed ID: 19118031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell lines used in prostate cancer research: a compendium of old and new lines--part 2.
    Sobel RE; Sadar MD
    J Urol; 2005 Feb; 173(2):360-72. PubMed ID: 15643173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo opossum xenograft model for cancer research.
    Wang Z; Hubbard GB; Pathak S; VandeBerg JL
    Cancer Res; 2003 Oct; 63(19):6121-4. PubMed ID: 14559788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer.
    Yonou H; Ochiai A; Ashimine S; Maeda H; Horiguchi Y; Yoshioka K; Ogawa Y; Hatano T; Tachibana M
    Prostate; 2007 Jun; 67(9):999-1009. PubMed ID: 17440967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
    Nishiyama T; Hashimoto Y; Takahashi K
    Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma.
    Hussein MR; Al-Assiri M; Musalam AO
    Exp Mol Pathol; 2009 Apr; 86(2):108-13. PubMed ID: 19111537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of genetically engineered mouse models of prostate cancer for nutrition and cancer chemoprevention research.
    Klein RD
    Mutat Res; 2005 Aug; 576(1-2):111-9. PubMed ID: 15885713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGF-8b induces growth and rich vascularization in an orthotopic PC-3 model of prostate cancer.
    Valta MP; Tuomela J; Vuorikoski H; Loponen N; Väänänen RM; Pettersson K; Väänänen HK; Härkönen PL
    J Cell Biochem; 2009 Jul; 107(4):769-84. PubMed ID: 19415685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples.
    Festuccia C; Angelucci A; Gravina GL; Muzi P; Miano R; Vicentini C; Bologna M
    Int J Oncol; 2005 May; 26(5):1353-62. PubMed ID: 15809728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines.
    Gu Y; Li H; Miki J; Kim KH; Furusato B; Sesterhenn IA; Chu WS; McLeod DG; Srivastava S; Ewing CM; Isaacs WB; Rhim JS
    Exp Cell Res; 2006 Apr; 312(6):831-43. PubMed ID: 16413016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy.
    Zitzmann S; Mier W; Schad A; Kinscherf R; Askoxylakis V; Krämer S; Altmann A; Eisenhut M; Haberkorn U
    Clin Cancer Res; 2005 Jan; 11(1):139-46. PubMed ID: 15671538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal stromal tumors (GISTs) on prostate needle biopsy: A clinicopathologic study of 8 cases.
    Herawi M; Montgomery EA; Epstein JI
    Am J Surg Pathol; 2006 Nov; 30(11):1389-95. PubMed ID: 17063078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A metastatic human prostate cancer model using intraprostatic implantation of tumor produced by PC-3 neolacZ transfected cells.
    Tsingotjidou AS; Ahluwalia R; Zhang X; Conrad H; Emmanouilides C
    Int J Oncol; 2003 Dec; 23(6):1569-74. PubMed ID: 14612928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical expression of prostate specific antigen (PSA) in benign and malignant tumors of the prostate.
    Dema A; Tudose N
    Rom J Morphol Embryol; 1998; 44(1-4):93-100. PubMed ID: 15678849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
    Dobosy JR; Roberts JL; Fu VX; Jarrard DF
    J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.